Skip to main content

Trade-Ideas LLC identified

Revance Therapeutics



) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Revance Therapeutics as such a stock due to the following factors:

  • RVNC has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $23.0 million.
  • RVNC has traded 77,460 shares today.
  • RVNC is trading at 2.05 times the normal volume for the stock at this time of day.
  • RVNC is trading at a new high 6.00% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in RVNC with the Ticky from Trade-Ideas. See the FREE profile for RVNC NOW at Trade-Ideas

More details on RVNC:

TheStreet Recommends

Revance Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. Currently there are 3 analysts that rate Revance Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Revance Therapeutics has been 347,300 shares per day over the past 30 days. Revance has a market cap of $1.0 billion and is part of the health care sector and drugs industry. Shares are up 108.4% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.


TheStreet Quant Ratings

rates Revance Therapeutics as a


. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

Highlights from the ratings report include:

  • REVANCE THERAPEUTICS INC's earnings per share declined by 35.0% in the most recent quarter compared to the same quarter a year ago. Earnings per share have declined over the last year. We anticipate that this should continue in the coming year. During the past fiscal year, REVANCE THERAPEUTICS INC reported poor results of -$3.10 versus -$0.57 in the prior year. For the next year, the market is expecting a contraction of 1.6% in earnings (-$3.15 versus -$3.10).
  • The company, on the basis of change in net income from the same quarter one year ago, has underperformed when compared to that of the S&P 500 and greatly underperformed compared to the Pharmaceuticals industry average. The net income has significantly decreased by 37.2% when compared to the same quarter one year ago, falling from -$13.98 million to -$19.18 million.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, REVANCE THERAPEUTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has declined marginally to -$13.71 million or 7.99% when compared to the same quarter last year. In conjunction, when comparing current results to the industry average, REVANCE THERAPEUTICS INC has marginally lower results.
  • Despite the stagnant revenue growth, the company outperformed against the industry average of 3.7%. Since the same quarter one year prior, revenues have remained constant. Even though the company's revenue remained stagnant, the earnings per share decreased.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.